Mallinckrodt plc company logo

# RNN 1st Gen Model Mallinckrodt plc Pharmaceutical preparations

Prediction models:
Subscribe >> Deal exit on
April 23, 2018
Deal entry on
April 23, 2018
3.99%Expected margin
78.85% successful of 52 deals
$ 13.76 Last close price
at 20-apr-2018


Model's trade recommendations No return for period yet

-3.36% Annual return

$1.21B Market Cap

β 1.12  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period
52wk return -18.83%
52wk Range
Sortino ratio 0.06
Sharpe ratio 0.05
Norm. RMSE 0.94%
Downside risk 27.07%
Volatility 29.79%
  • BUY Analysts consensus recommendation

Mallinckrodt Plc. is engaged in pharmaceuticals business. It develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. The company's Specialty Pharmaceuticals segment includes branded and generic drugs and Medical Imaging segment includes contrast media and nuclear imaging agents. Mallinckrodt Plc. is based in Dublin, Ireland.

Industry sector: Medical

Sector classification: Pharmaceutical preparations

Deep Learning based analysis and prediction model for Mallinckrodt plc (MNK) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 22, 2015.

Market data for MNK model training are being downloaded from the Quandl premium datasets on a daily basis.

Model is being retrained on a daily basis.

Float 85M
P/E 1.86
Shares Outstanding 86M
% Held by Insiders 1.80%
% Held by Institutions NaN%
EPS (last reported FY) $7.49
EPS (last reported Q) $2.01
EPS, estimated (last reported Q) $1.72
Total revenues $3 B
Net income $2 B